🇺🇸 FDA
Pipeline program

PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

2024/3967

Phase 2 small_molecule active

Quick answer

PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL for Advanced non-small cell lung cancer is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Advanced non-small cell lung cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials